Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of adjuvant Docetaxel/Cyclophosphamide vs EC followed by Docetaxel in HER2-negative early breast cancer
2008-004263-19Phase 3Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Oct 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel in breast cancer (2 arms), sponsored by Westdeutsche Studiengruppe. Primary endpoints: Unacceptable toxicity and Event-free survival. Started Oct 2008; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-004263-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004263-19.